Advances in Therapy

, Volume 25, Issue 9, pp 894–913

LG839: Anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome

  • Kenneth Blum
  • Amanda L. C. Chen
  • Thomas J. H. Chen
  • Patrick Rhoades
  • Thomas J. Prihoda
  • B. William Downs
  • Roger L. Waite
  • Lonna Williams
  • Eric R. Braverman
  • Dasha Braverman
  • Vanessa Arcuri
  • Mallory Kerner
  • Seth H. Blum
  • Tomas Palomo
Original Research

Abstract

Introduction

This study systematically assessed the weight management effects of a novel experimental DNA-customized nutraceutical, LG839 (LifeGen®, Inc., La Jolla, CA, USA).

Methods

A total of 1058 subjects who participated in the overall D.I.E.T. study were genotyped and administered an LG839 variant based on polymorphic outcomes. A subset of 27 self-identified obese subjects of Dutch descent, having the same DNA pattern of four out of the five candidate genes tested (chi-square analysis) as the entire data set, was subsequently evaluated. Simple t tests comparing a number of weight management parameters before and after 80 days of treatment with LG839 were performed.

Results

Significant results were observed for weight loss, sugar craving reduction, appetite suppression, snack reduction, reduction of late night eating (all P<0.01), increased perception of overeating, enhanced quality of sleep, increased happiness (all P<0.05), and increased energy (P<0.001). Polymorphic correlates were obtained for a number of genes (LEP, PPAR-γ2, MTHFR, 5-HT2A, and DRD2 genes) with positive clinical parameters tested in this study. Of all the outcomes and gene polymorphisms, only the DRD2 gene polymorphism (A1 allele) had a significant Pearson correlation with days on treatment (r=0.42, P=0.045).

Conclusion

If these results are confirmed in additional rigorous, controlled studies, we carefully suggest that DNA-directed targeting of certain regulator genes, along with customized nutraceutical intervention, provides a unique framework and strategic modality to combat obesity.

Keywords

LG839 neurotransmitters obesity reward deficiency syndrome sugar craving behavior weight loss 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer Healthcare Communications 2008

Authors and Affiliations

  • Kenneth Blum
    • 1
    • 2
    • 3
    • 4
    • 11
  • Amanda L. C. Chen
    • 5
    • 6
  • Thomas J. H. Chen
    • 5
    • 6
  • Patrick Rhoades
    • 7
  • Thomas J. Prihoda
    • 8
  • B. William Downs
    • 2
  • Roger L. Waite
    • 2
  • Lonna Williams
    • 2
  • Eric R. Braverman
    • 9
    • 3
  • Dasha Braverman
    • 3
  • Vanessa Arcuri
    • 3
  • Mallory Kerner
    • 3
  • Seth H. Blum
    • 4
  • Tomas Palomo
    • 10
  1. 1.Department of Physiology & PharmacologyWake Forest University School of MedicineWinston-SalemUSA
  2. 2.LifeGen®, Inc.La JollaUSA
  3. 3.PATH Medical & Research FoundationNew YorkUSA
  4. 4.Synaptamine™, Inc.San AntonioUSA
  5. 5.Chang Jung Christian UniversityTainanTaiwan
  6. 6.Changhua Christian HospitalChanghuaTaiwan
  7. 7.Comprehensive Obesity ClinicModestoUSA
  8. 8.Department of PathologyUniversity of Texas Health Science CenterSan AntonioUSA
  9. 9.Department of NeurosurgeryWeill Cornell Medical CollegeNew YorkUSA
  10. 10.Hospital UniversitarioMadridSpain
  11. 11.Department of Physiology & PharmacologyWake Forest University School of MedicineWinston-SalemUSA
  12. 12.Chang Jing Christian UniversityTainanTaiwan

Personalised recommendations